These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21442198)

  • 1. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
    Fagerlin A; Dillard AJ; Smith DM; Zikmund-Fisher BJ; Pitsch R; McClure JB; Greene S; Alford SH; Nair V; Hayes DF; Wiese C; Ubel PA
    Breast Cancer Res Treat; 2011 Jun; 127(3):681-8. PubMed ID: 21442198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
    Fagerlin A; Zikmund-Fisher BJ; Nair V; Derry HA; McClure JB; Greene S; Stark A; Hensley Alford S; Lantz P; Hayes DF; Wiese C; Claud Zweig S; Pitsch R; Jankovic A; Ubel PA
    Breast Cancer Res Treat; 2010 Feb; 119(3):613-20. PubMed ID: 19908143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials.
    Martino S; Costantino J; McNabb M; Mershon J; Bryant K; Powles T; Secrest RJ
    Oncologist; 2004; 9(2):116-25. PubMed ID: 15047916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.
    Legault C; Maki PM; Resnick SM; Coker L; Hogan P; Bevers TB; Shumaker SA
    J Clin Oncol; 2009 Nov; 27(31):5144-52. PubMed ID: 19770382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.
    McIntosh JG; Minshall J; Saya S; Bickerstaffe A; Hewabandu N; Qama A; Emery JD
    Br J Gen Pract; 2019 Dec; 69(689):e836-e842. PubMed ID: 31636127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.
    Levine M; Moutquin JM; Walton R; Feightner J;
    CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
    Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
    Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From adjuvant therapy to breast cancer prevention: BCPT and STAR.
    Dunn BK; Ford LG
    Breast J; 2001; 7(3):144-57. PubMed ID: 11469927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
    JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
    Korfage IJ; Fuhrel-Forbis A; Ubel PA; Zikmund-Fisher BJ; Greene SM; McClure JB; Smith DM; Alford SH; Fagerlin A
    Breast Cancer Res; 2013; 15(5):R74. PubMed ID: 24004815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
    Dickler MN; Norton L
    Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a randomized trial of a web-based, tailored decision aid for women at high risk for breast cancer.
    Banegas MP; McClure JB; Barlow WE; Ubel PA; Smith DM; Zikmund-Fisher BJ; Greene SM; Fagerlin A
    Patient Educ Couns; 2013 Jun; 91(3):364-71. PubMed ID: 23395006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of breast cancer.
    Zelnak AB; O'Regan RM
    Curr Probl Cancer; 2004; 28(4):201-17. PubMed ID: 15318323
    [No Abstract]   [Full Text] [Related]  

  • 17. Recruitment of women into trials.
    Benson JR
    Lancet; 2002 Jan; 359(9301):164. PubMed ID: 11809281
    [No Abstract]   [Full Text] [Related]  

  • 18. Raloxifene in breast cancer prevention.
    Gennari L; Merlotti D; Paola VD; Nuti R
    Expert Opin Drug Saf; 2008 May; 7(3):259-70. PubMed ID: 18462184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
    Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Wolmark N
    Clin Breast Cancer; 2002 Jun; 3(2):153-9. PubMed ID: 12123540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
    Visvanathan K; Chlebowski RT; Hurley P; Col NF; Ropka M; Collyar D; Morrow M; Runowicz C; Pritchard KI; Hagerty K; Arun B; Garber J; Vogel VG; Wade JL; Brown P; Cuzick J; Kramer BS; Lippman SM;
    J Clin Oncol; 2009 Jul; 27(19):3235-58. PubMed ID: 19470930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.